Comparison of nuclear grade and immunohistochemical features in situ and invasive components of ductal carcinoma of breast

Aguiar, Fernando Nalesso; Mendes, Henrique; Bacchi, Carlos E.; Carvalho, Filomena Marino

doi:10.1590/s0100-72032013000300002

Cited by 18 publications

(21 citation statements)

References 25 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other studies also have shown that in-situ and invasive stages of breast ductal carcinoma are similar in gene expression, suggesting that invasiveness necessary changes are already present in the in-situ lesions that will later progress to invasive ones. Therefore, DCIS should acquire enabling gene expression changes much before morphological alterations and invasiveness [5,17,18]. In this study, we found only two differentially expressed genes between IDC pure and DCIS pure .…”

Section: Discussionmentioning

confidence: 60%

Potential biomarkers of ductal carcinoma in situ progression

Dettogni

Stur

Laus

et al. 2019

Preprint

View full text Add to dashboard Cite

Background Ductal carcinoma in situ is a non-obligate precursor of invasive breast carcinoma and presents a potential risk of over or undertreatment. Finding molecular biomarkers of disease progression could allow for more adequate patient’s treatment. Our aim was to identify potentially biomarkers that can predict invasiveness risk.Methods In this epithelial cell-based study archival formalin-fixed paraffin-embedded blocks from six patients diagnosed with invasive lesions (pure invasive ductal carcinoma), six with in-situ lesions (pure ductal carcinoma in situ) , six with synchronous lesions (invasive ductal carcinoma with an in-situ component) and three non-neoplastic breast epithelium tissues were analyzed by gene expression profiling of 770 genes, using the nCounter® PanCancer Pathways panel of NanoString Technologies.Results The results showed that in comparison with non-neoplastic tissue the pure ductal carcinoma in situ was one with the most altered gene expression profile. Comparing pure ductal carcinoma in situ and in-situ component six differentially expressed genes were found, three of them ( FGF2 , GAS1 and SFRP1 ), play a role in cell invasiveness. Importantly, these genes were also differentially expressed between invasive and noninvasive groups and were negatively regulated in later stages of carcinogenesis.Conclusions We propose these three genes ( FGF2 , GAS1 and SFRP1 ) as potential biomarkers of ductal carcinoma in situ progression, suggesting that their downregulation may be involved in the transition of stationary to migrating invasive epithelial cells.

show abstract

Section: Discussionmentioning

confidence: 60%

Potential biomarkers of ductal carcinoma in situ progression

Dettogni

Stur

Laus

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…Other studies also have shown that in-situ and invasive stages of breast ductal carcinoma are similar in gene expression, suggesting that invasiveness necessary changes are already present in the in-situ lesions that will later progress to invasive ones. Therefore, DCIS should acquire enabling gene expression changes much before morphological alterations and invasiveness [5,18,19]. In this study, we found only 2 differentially expressed genes between IDC pure and DCIS pure .…”

Section: Discussionmentioning

confidence: 63%

Potential biomarkers of ductal carcinoma in situ progression

Dettogni

Stur

Laus

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Ductal carcinoma in situ is a non-obligate precursor of invasive breast carcinoma and presents a potential risk of over or undertreatment. Finding molecular biomarkers of disease progression could allow for more adequate patient treatment. We aimed to identify potential biomarkers that can predict invasiveness risk.Methods In this epithelial cell-based study archival formalin-fixed paraffin-embedded blocks from six patients diagnosed with invasive lesions (pure invasive ductal carcinoma), six with in-situ lesions (pure ductal carcinoma in situ) , six with synchronous lesions (invasive ductal carcinoma with an in-situ component) and three non-neoplastic breast epithelium tissues were analyzed by gene expression profiling of 770 genes, using the nCounter® PanCancer Pathways panel of NanoString Technologies. Results The results showed that in comparison with non-neoplastic tissue the pure ductal carcinoma in situ was one with the most altered gene expression profile. Comparing pure ductal carcinoma in situ and in-situ component six differentially expressed genes were found, three of them ( FGF2 , GAS1, and SFRP1 ), play a role in cell invasiveness. Importantly, these genes were also differentially expressed between invasive and noninvasive groups and were negatively regulated in later stages of carcinogenesis. Conclusions We propose these three genes ( FGF2 , GAS1, and SFRP1 ) as potential biomarkers of ductal carcinoma in situ progression, suggesting that their downregulation may be involved in the transition of stationary to migrating invasive epithelial cells.

show abstract

“…A limited number of studies have addressed the correlation between CEA and molecular subtypes (Shao et al, 2015). Based on the immunohistochemical assessment of ER, PR, HER2, p53 and Ki57, a panel of markers plays a necessary role in the individualized care of BC (Aguiar et al, 2013). No correlation was observed between CEA mRNA, serum and immunohistochemical parameters.…”

Section: Discussionmentioning

confidence: 99%